The DOI matches its Crossref record; 52 of the 55 references it cites were found in a registry or an index.
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Abstract
Context Bladder cancer has become a common cancer globally, with an estimated 430 000 new cases diagnosed in 2012. Objective We examine the most recent global bladder cancer incidence and mortality patterns and trends, the current understanding of the aetiology of the disease, and specific issues that may influence the registration and reporting of bladder cancer. Evidence acquisition Global bladder cancer incidence and mortality statistics are based on data from the International Agency for Research on Cancer and the World Health Organisation (Cancer Incidence in Five Continents, GLOBOCAN, and the World Health Organisation Mortality). Evidence synthesis Bladder cancer ranks as the ninth most frequently-diagnosed cancer worldwide, with the highest incidence rates observed in men in Southern and Western Europe, North America, as well in certain countries in Northern Africa or Western Asia. Incidence rates are consistently lower in women than men, although sex differences varied greatly between countries. Diverging incidence trends were also observed by sex in many countries, with stabilising or declining rates in men but some increasing trends seen for women. Bladder cancer ranks 13th in terms of deaths ranks, with mortality rates decreasing particularly in the most developed countries; the exceptions are countries undergoing rapid economic transition, including in Central and South America, some central, southern, and eastern European countries, and the Baltic countries. Conclusions The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking, although infection with Schistosoma haematobium and other risk factors are major causes in selected populations. Differences in coding and registration practices need to be considered when comparing bladder cancer statistics geographically or over time. Patient summary The main risk factor for bladder cancer is tobacco smoking. The observed patterns and trends of bladder cancer incidence worldwide appear to reflect the prevalence of tobacco smoking.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The epidemiology of bladder cancer varies by region, with tobacco smoking, occupational exposures (e.g., aromatic amines), and arsenic contamination of drinking water among the putative causes in industrialized countries.159,160”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“Diverging bladder cancer incidence trends have been observed by sex since the 1990s, with rates tending to decrease or stabilize in men but increase among women in certain European countries (e.g., in Spain, the Netherlands, Germany, and Belarus).160,162,163”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“comparing trends in bladder cancer mortality rates may be more suitable for assessing progress in disease control.160,166”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“Of note, there may be artifactual changes in incidence because of differences in coding and registration practice concerning inclusion or otherwise of noninvasive carcinomas.160,166,167”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
In the citing paper
“increases in mortality rates have also been reported among men in Thailand, Israel, and Slovakia and among women in Thailand, Japan, Croatia, and Poland.160”
From Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. (2024) · cites this paper as [160]
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Self-citationCancer Incidence in Five Continents
Doll, R., Muir, C. S., & Waterhouse, J. A. H. (1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,485
The United Nations Development Programme
Oestreich, J. E. (2017) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780190637347.003.0003 · Cited by 4,875
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
Babjuk, M. M., Andreas Böhle, E., Burger, M., Čapoun, O., Cohen, D. L., Compérat, É., Hernández, V., KAASINEN, E. S., Palou, J., Morgan Rouprêt, A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.041 · Cited by 2,240
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Burger, M., Catto, J. W. F., Dalbagni, G. M., Grossman, H. B., Herr, H. W., Karakiewicz, P. I., Kassouf, W., Kiemeney, L. A. L. M., Vecchia, C. L., Shariat, S. F., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.07.033 · Cited by 2,212
Steinmann, P., Keiser, J., Bos, R., Tanner, M., & Utzinger, J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70521-7 · Cited by 2,146
Smoking prevalence and cigarette consumption in 187 countries, 1980-2012
Ng, M., Freeman, M. K., Fleming, T. D., Robinson, M., Dwyer-Lindgren, L., Thomson, B., Wollum, A., Sanman, E., Wulf, S., Lopez, A. D., et al. (2014) · JAMA · doi:10.1001/jama.2013.284692 · Cited by 1,576
Estimating average annual per cent change in trend analysis
Clegg, L. X., Hankey, B. F., Tiwari, R. C., Feuer, E. J., & Edwards, B. K. (2009) · Statistics in Medicine · doi:10.1002/sim.3733 · Cited by 1,271
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W. G., Compérat, E., Sylvester, R. J., Kaasinen, E., Böhle, A., Palou Redorta, J., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.06.003 · Cited by 1,174
Research works printed but not linked: 1
- Loader C. Smoothing: Local Regression Techniques Web site. http://hdl.handle.net/10419/22186.
Cited by
Sorted by citations
Items 201–300 of 1,000
Murthy, S. S., Trapani, D., Cao, B., Bray, F., Murthy, S., Kingham, T. P., Are, C., & Ilbawi, A. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00274-2 · Cited by 63
Self-citationMiller, N. J., Khaki, A. R., Diamantopoulos, L. N., Bilen, M. A., Santos, V. S., Agarwal, N., Morales‐Barrera, R., Devitt, M. E., Nelson, A. A., Hoimes, C. J., et al. (2020) · The Journal of Urology · doi:10.1097/ju.0000000000000761 · Cited by 62
Urothelial generation and regeneration in development, injury, and cancer
Wang, C., Ross, W. T., & Mysorekar, I. U. (2017) · Developmental Dynamics · doi:10.1002/dvdy.24487 · Cited by 62
Liang, Y., Ye, F., Xu, C., Zou, L., Hu, Y. Y., Hu, J., & Jiang, H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08687-7 · Cited by 62
Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer
Giannopoulou, A. F., Velentzas, A. D., Konstantakou, E. G., Avgeris, M., Katarachia, S. A., Papandreou, N. C., Kalavros, N., Mpakou, V., Iconomidou, V. A., Anastasiadou, E., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061291 · Cited by 62
Yi, R., Lin, A., Cao, M., Xu, A., Luo, P., & Zhang, J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00933 · Cited by 60
Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism
Elbadawy, M., Sato, Y., Mori, T., Goto, Y., Hayashi, K., Yamanaka, M., Azakami, D., Uchide, T., Fukushima, R., Yoshida, T., et al. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1919004 · Cited by 61
Kouba, E., & Liang Cheng, C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.7013 · Cited by 61
The clinical significance of COL5A2 in patients with bladder cancer
Zeng, X., Liu, X., Liu, T.-Z., & Wang, X. (2018) · Medicine · doi:10.1097/md.0000000000010091 · Cited by 60
Emerging Biomarkers in Bladder Cancer Identified by Network Analysis of Transcriptomic Data
Giulietti, M., Occhipinti, G., Righetti, A., Bracci, M., Conti, A., Ruzzo, A., Cerigioni, E., Cacciamani, T., Principato, G., & Piva, F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00450 · Cited by 60
Kolawole, O. M., Lau, W. M., & Khutoryanskiy, V. V. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.006 · Cited by 60
Cancer mortality predictions for 2019 in Latin America
Carioli, G., Bertuccio, P., Malvezzi, M., Rodríguez, T., Levi, F., Boffetta, P., Vecchia, C. L., & Negri, E. (2019) · International Journal of Cancer · doi:10.1002/ijc.32749 · Cited by 60
Sugawara, S., Yamada, Y., Arai, T., Okato, A., Idichi, T., Kato, M., Koshizuka, K., Ichikawa, T., & Seki, N. (2018) · Journal of Human Genetics · doi:10.1038/s10038-018-0437-8 · Cited by 59
LncRNA KCNQ1OT1 facilitates the progression of bladder cancer by targeting MiR-218-5p/HS3ST3B1
Li, Y., Shi, B., Dong, F., Zhu, X., Liu, B., & Liu, Y. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-00211-6 · Cited by 59
Tokuyama, N., Saito, A., Muraoka, R., Matsubara, S., Hashimoto, T., Satake, N., Matsubayashi, J., Nagao, T., Mirza, A. H., Graf, H.-P., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00955-y · Cited by 59
Quality Control Indicators for Transurethral Resection of Non–Muscle-Invasive Bladder Cancer
Akand, M., Muilwijk, T., Raskin, Y., Vrieze, M. D., Joniau, S., & der Aa, F. V. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.04.014 · Cited by 59
Yang, R., Xu, J., Hua, X., Tian, Z., Xie, Q., Li, J., Jiang, G., Cohen, M. D., Sun, H., & Huang, C. (2019) · Oncogene · doi:10.1038/s41388-019-1120-z · Cited by 59
Fu, G., Xu, Z., Chen, X., Pan, H., Wang, Y., & Jin, B. (2020) · Journal of Cancer · doi:10.7150/jca.35372 · Cited by 58
Lai, M., Liu, G., Li, R., Bai, H., Zhao, J., Xiao, P., & Mei, J. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15122 · Cited by 58
Moschini, M., Xylinas, E. N., Zamboni, S., Mattei, A., Niegisch, G., Yu, E. Y., Bamias, A., Agarwal, N., Sridhar, S. S., Sternberg, C. N., et al. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.06.014 · Cited by 58
van Doeveren, T., van de Werken, H. J. G., van Riet, J., Aben, K. K. H., van Leeuwen, P. J., Zwarthoff, E. C., & Boormans, J. L. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.01.008 · Cited by 57
Abufaraj, M. M., Gust, K. M., Moschini, M., Foerster, B., Soria, F., Mathiéu, R., & Shariat, S. F. (2016) · Translational Andrology and Urology · doi:10.21037/tau.2016.08.23 · Cited by 58
DNA Repair Pathway Alterations in Bladder Cancer
Mouw, K. W. (2017) · Cancers · doi:10.3390/cancers9040028 · Cited by 57
Li, B., Xie, F., Zheng, F., Jiang, G., Zeng, F., & Xiao, X. (2017) · Current Medical Science · doi:10.1007/s11596-017-1822-9 · Cited by 56
Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells
Zhang, L., Yang, G., Zhang, R., Dong, L., Chen, H., Bo, J., Xue, W., & Huang, Y. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4423 · Cited by 57
Chen, Y., Yang, C., Shao, P., Huang, C., & Yip, H. (2018) · Journal of Pineal Research · doi:10.1111/jpi.12536 · Cited by 57
Hu, J., Chen, J.-B., Cui, Y., Zhu, Y.-W., Ren, W.-B., Zhou, X., Liu, L.-F., Chen, H.-Q., & Zu, X.-B. (2018) · Medicine · doi:10.1097/md.0000000000011596 · Cited by 56
van Doeveren, T., van der Mark, M., van Leeuwen, P. J., Boormans, J. L., & Aben, K. K. H. (2021) · British Journal of Urology · doi:10.1111/bju.15389 · Cited by 56
HBO1 promotes cell proliferation in bladder cancer via activation of Wnt/β‐catenin signaling
Chen, Z., Zhou, L., Wang, L., Kazobinka, G., Zhang, X., Han, X., Li, B., & Hou, T. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22715 · Cited by 56
Schwamborn, K., Ammann, J. U., Knüchel, R., Hartmann, A., Baretton, G. B., Lasitschka, F., Schirmacher, P., Braunschweig, T. A., Tauber, R., Erlmeier, F., et al. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02610-z · Cited by 56
Cao, J., Yang, X. L., Li, J., Wu, H., Li, P., Yao, Z., Dong, Z., & Tian, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01533 · Cited by 56
The top 100 most cited manuscripts in bladder cancer: A bibliometric analysis (review article)
Mainwaring, A., Bullock, N., Ellul, T., Hughes, O., & Featherstone, J. (2020) · International Journal of Surgery · doi:10.1016/j.ijsu.2020.01.128 · Cited by 56
Wang, Z., Shang, Y., Luan, T., Duan, Y., Wang, J., Wang, H., & Hao, J. (2020) · Cancer Imaging · doi:10.1186/s40644-020-00304-3 · Cited by 56
Chen, L., Yang, X. W., Zhao, J., Xiong, M., Almaraihah, R. A., Chen, Z., & Hou, T. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01592-0 · Cited by 56
Yoshida, T., Sopko, N. A., Kates, M. R., Liu, X., Joice, G. A., McConkey, D. J., & Bivalacqua, T. J. (2018) · Oncotarget · doi:10.18632/oncotarget.24308 · Cited by 55
Pichler, R., Tulchiner, G. A., Fritz, J., Schaefer, G., Horninger, W., & Heidegger, I. M. (2017) · International Journal of Medical Sciences · doi:10.7150/ijms.19929 · Cited by 55
Sabo, A. A., Birolo, G., Naccarati, A., Dragomir, M. P., Aneli, S., Allione, A., Oderda, M., Allasia, M., Gontero, P., Sacerdote, C., et al. (2020) · Cancers · doi:10.3390/cancers12061507 · Cited by 55
Barone, B., Calogero, A., Scafuri, L., Ferro, M., Lucarelli, G. T., Zazzo, E. D., Sicignano, E., Falcone, A., Romano, L., Luca, L. D., et al. (2022) · Cancers · doi:10.3390/cancers14102545 · Cited by 53
Lee, S., Jue, M., Lee, K.-H., Paulson, B., Oh, J., Cho, M., & Kim, J. K. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115915 · Cited by 54
Grivas, P. D., Mortazavi, A., Picus, J., Hahn, N. M., Milowsky, M. I., Hart, L. L., Alva, A. S., Joaquim Bellmunt, B., Pal, S. K., Bambury, R. M., et al. (2018) · Cancer · doi:10.1002/cncr.31817 · Cited by 54
Impact of perioperative pain management on cancer recurrence: an ASRA/ESRA special article
Missair, A., Cata, J. P., Votta‐Velis, G., Johnson, M. Z., Borgeat, A., Tiouririne, M., Gottumukkala, V., Buggy, D. J., Vallejo, R., de Marrero, E. B., et al. (2019) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2018-000001 · Cited by 54
Witzke, K. E., Großerueschkamp, F., Jütte, H., Horn, M., Roghmann, F., von Landenberg, N., Bracht, T., Kallenbach‐Thieltges, A., Käfferlein, H. U., Brüning, T., et al. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.11.018 · Cited by 52
Urine and Serum Exosomes as Novel Biomarkers in Detection of Bladder Cancer
El-Sharkawi, F., Sabah, M. E., Shabayek, M. I., & Khaled, H. M. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.7.2219 · Cited by 54
Wang, Y., Shi, F., Xia, Y., & Zhao, H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28024 · Cited by 53
He, Q., Yan, D., Dong, W., Bi, J., Huang, L., Yang, M., Huang, J., Qin, H., & Lin, T. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.12.014 · Cited by 53
Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer
Wang, Y., Chen, L., Yu, M., Fang, Y., Qian, K., Wang, G., Ju, L., Xiao, Y., & Wang, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3400 · Cited by 53
Tong, H., Li, T., Gao, S., Yin, H., Cao, H., & He, W. (2020) · Bioscience Reports · doi:10.1042/bsr20203944 · Cited by 53
Autophagy-Related Long Non-coding RNA Is a Prognostic Indicator for Bladder Cancer
Wan, J., Guo, C., Fang, H., Xu, Z., Hu, Y., & Luo, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.647236 · Cited by 53
The androgen receptor in bladder cancer
Chen, J., Huang, C., Quan, C., Zu, X., Ou, Z., Tsai, Y., Messing, E. M., Yeh, S., & Chang, C. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00761-y · Cited by 53
Chen, H., Li, X., Broderick, N. G. R., Liu, Y., Zhou, Y., Han, J., & Xu, W. (2018) · Journal of Biophotonics · doi:10.1002/jbio.201800016 · Cited by 53
Avgeris, M., Tsilimantou, A., Levis, P. K., Tokas, T., Sideris, D. C., STRAVODIMOS, K. G., Ardavanis, A. S., & Scorilas, A. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0320-6 · Cited by 51
Poinard, B., Lam, S. A. E., Neoh, K. G., & Kah, J. C. Y. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.02.041 · Cited by 53
CircHIPK3: a promising cancer-related circular RNA.
Zhang, Y., Liu, Q., & Liao, Q. (2020) · PubMed Central · Cited by 53
Yamada, Y., Kato, M., Arai, T., Sanada, H., Uchida, A., Misono, S., Sakamoto, S., Komiya, A., Ichikawa, T., & Seki, N. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12532 · Cited by 52
Deep learning based digital cell profiles for risk stratification of urine cytology images
Awan, R., Benes, K., Azam, A. S., Song, T., Shaban, M., Verrill, C. L., Tsang, Y. W., Snead, D. R. J., Minhas, F., & Rajpoot, N. (2021) · Cytometry Part A · doi:10.1002/cyto.a.24313 · Cited by 52
Leonardo, C., Flammia, R. S., Lucciola, S., Proietti, F., Pecoraro, M., Bucca, B., Licari, L. C., Borrelli, A., Bologna, E., Landini, N., et al. (2023) · Cancers · doi:10.3390/cancers15030580 · Cited by 52
Li, Q., Zhang, P., Wang, P., Yan, C., Wang, K., Yang, W., Dang, D., & Cao, L. (2024) · Aggregate · doi:10.1002/agt2.676 · Cited by 52
Mason, S. J., Catto, J. W. F., Downing, A., Bottomley, S. E., Glaser, A., & Wright, P. (2018) · British Journal of Urology · doi:10.1111/bju.14368 · Cited by 52
Xu, Y., Wu, G., Li, J., Li, J., Ruan, N., Ma, L., Han, X., Wei, Y., Li, L., Zhang, H., et al. (2020) · BioMed Research International · doi:10.1155/2020/8283401 · Cited by 52
Cai, X., Qu, L., Yang, J., Xu, J., Sun, L., Wei, X., Qu, X., Bai, T., Guo, Z., & Zhu, Y. (2020) · Cancer Medicine · doi:10.1002/cam4.3263 · Cited by 52
Zeng, M., Su, Y., Li, K., Jin, D., Li, Q., Li, Y., & Zhou, B. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01222 · Cited by 52
Mandlik, D. S., & Mandlik, S. K. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1834591 · Cited by 52
Anticancer and apoptosis inducing potential of quercetin against a wide range of human malignancies
Shahbaz, M., Naeem, H., Momal, U., Imran, M., Alsagaby, S. A., Abdulmonem, W. A., Waqar, A. B., El-Ghorab, A. H., Ghoneim, M. M., Abdelgawad, M. A., et al. (2023) · International Journal of Food Properties · doi:10.1080/10942912.2023.2252619 · Cited by 51
Organochlorine and organophosphorus pesticides and bladder cancer: A case‐control study
Mortazavi, N., Asadikaram, G., Ebadzadeh, M. R., Kamalati, A., Pakmanesh, H., Dadgar, R., Moazed, V., Paydar, P., Fallah, H., & Abolhassani, M. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28746 · Cited by 51
Rompré‐Brodeur, A., Shinde-Jadhav, S., Ayoub, M., Piccirillo, C. A., Seuntjens, J. P., Brimo, F., Mansure, J. J., & Kassouf, W. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0986 · Cited by 51
Therapeutic and prognostic implications of NOTCH and MAPK signaling in bladder cancer
Schulz, G. B., Elezkurtaj, S., Börding, T., Schmidt, E. M., Elmasry, M., Stief, C. G., Kirchner, T., Karl, A., & Horst, D. A. (2021) · Cancer Science · doi:10.1111/cas.14878 · Cited by 51
Trends in Bladder Cancer Incidence and Mortality: Success or Disappointment?
Babjuk, M. M. (2016) · European Urology · doi:10.1016/j.eururo.2016.06.040 · Cited by 51
Prognostic Value of Long Non-Coding RNA Signatures in Bladder Cancer
He, A., He, S., Ding, P., Zhan, Y., Li, Y., Chen, Z., Gong, Y., Li, X., & Zhou, L. (2019) · Aging · doi:10.18632/aging.102185 · Cited by 50
Liu, T., Lu, Q., Liu, J., Xie, S., Feng, B., Zhu, W., Liu, M., Liu, Y., Zhou, X., Sun, W., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2226-5 · Cited by 49
Xu, H., Liu, Z., Weng, S., Dang, Q., Ge, X., Zhang, Y., Ren, Y., Xing, Z., Chen, S., Zhou, Y., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13313 · Cited by 50
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
Maiorano, B. A., Maïo, M. D., Cerbone, L., Maiello, E., Procopio, G., Roviello, G., MeetURO Group, Accettura, C., Aieta, M., Alberti, M., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.1215 · Cited by 55
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Miranda‐Filho, A., Briganti, A., Jemal, A., & Bray, F. (2025) · European Urology · doi:10.1016/j.eururo.2025.12.011 · Cited by 51
Self-citationMostafid, H. A., Porta, N., Cresswell, J., Griffiths, T. R. L., Kelly, J. D., Penegar, S., Davenport, K., McGrath, J. S., Campain, N. J., Cooke, P. W., et al. (2020) · British Journal of Urology · doi:10.1111/bju.15038 · Cited by 50
Huang, W., Lu, Y., Wang, F., Huang, X., & Yu, Z. (2018) · Gene · doi:10.1016/j.gene.2018.08.036 · Cited by 49
Huang, S.-Y., Chang, S.-F., Liao, K., & Chiu, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081616 · Cited by 49
Shrestha, S., Zhu, J., Wang, Q., Du, X., Liu, F., Jiang, J., Song, J., Xing, J., Sun, D., Hou, Q., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4097 · Cited by 52
Abufaraj, M. M., Shariat, S. F., Foerster, B., Pozo, C. D., Moschini, M., D’Andrea, D., Mathiéu, R., Susani, M., Czech, A. K., Karakiewicz, P. I., et al. (2017) · World Journal of Urology · doi:10.1007/s00345-017-2116-3 · Cited by 49
MMP‐2 and MMP‐9 as prognostic markers for the early detection of urinary bladder cancer
Fouad, H. H., Salem, H. K., Ellakwa, D. E., & Abdel‐Hamid, M. (2018) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22275 · Cited by 49
Shen, C., Wu, Z., Wang, Y., Gao, S., Da, L., Xie, L., Qie, Y., Tian, D., & Hu, H. (2020) · Cancer Medicine · doi:10.1002/cam4.3006 · Cited by 49
Mutational Landscape and Environmental Effects in Bladder Cancer
Hayashi, T., Fujita, K., Hayashi, Y., Hatano, K., Kawashima, A., McConkey, D. J., & Nonomura, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176072 · Cited by 49
Du, Y., Miao, W., Jiang, X. W., Cao, J., Wang, B., Wang, Y., Yu, J., Wang, X., & Liu, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683951 · Cited by 50
Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer
Yang, G., Bondaruk, J. E., Cogdell, D. E., Wang, Z., Lee, S., Lee, J. G., Zhang, S., Choi, W., Wang, Y., Liang, Y., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101201 · Cited by 49
Lu, J., Xia, Q., Lu, Y., Liu, Z., Zhou, P., Hu, H., & Wang, S. (2020) · Cancer Medicine · doi:10.1002/cam4.3513 · Cited by 48
Wang, L., Li, H., Qiao, Q., Ge, Y., Ma, L., & Wang, Q. (2020) · Aging · doi:10.18632/aging.103971 · Cited by 48
Zheng, B., Liu, Z., Wang, H., Sun, L., Lai, W., Zhang, H., Wang, J., Liu, Y., Qin, X., Qi, X., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.055 · Cited by 48
VI-RADS in bladder cancer: Overview, pearls and pitfalls
Lai, A. L., & Law, Y. M. (2023) · European Journal of Radiology · doi:10.1016/j.ejrad.2022.110666 · Cited by 48
Juráček, J., Peltanová, B., Doležel, J., Fedorko, M., Pacík, D., Radová, L., Veselá, P., Svoboda, M., Slabý, O., & Staník, M. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13487 · Cited by 48
Update on the Treatment of Metastatic Urothelial Carcinoma
Bukhari, N., Al-Shamsi, H. O., & Azam, F. (2018) · The Scientific World JOURNAL · doi:10.1155/2018/5682078 · Cited by 48
Deng, Y., Bi, R., Guo, H., Yang, J., Du, Y., Wang, C., & Wei, W. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.30847 · Cited by 48
Kaouk, J. H., Garisto, J., Eltemamy, M. M., & Bertolo, R. G. (2019) · Urology · doi:10.1016/j.urology.2019.03.023 · Cited by 48
Emerging therapeutic agents for genitourinary cancers
Zarrabi, K. K., Paroya, A., & Wu, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0780-z · Cited by 49
Multiparametric Cystoscopy for Detection of Bladder Cancer Using Real-time Multispectral Imaging
KRIEGMAIR, M. C., Röther, J., Grychtol, B., Theuring, M., Ritter, M., Güneş, Ç., Michel, M. S., Deliolanis, N. C., & Bolenz, C. (2019) · European Urology · doi:10.1016/j.eururo.2019.08.024 · Cited by 48
Deep Learning data integration for better risk stratification models of bladder cancer.
Poirion, O., Chaudhary, K., & Garmire, L. X. (2018) · Europe PMC (PubMed Central) · Cited by 48
Quinazoline Derivatives as Potential Therapeutic Agents in Urinary Bladder Cancer Therapy
Wdowiak, P., Matysiak, J., Kuszta, P., Czarnek, K., Niezabitowska, E., & Baj, T. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.765552 · Cited by 48
Lyu, Z., Wang, Y., Huang, J. L., Chen, M., Wu, S. Y., Yan, Q., Zhang, Y., Tang, Y., Jiang, C., Li, L., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.004 · Cited by 47
RetractedNuclear Factor κB Signaling and Its Related Non-coding RNAs in Cancer Therapy
Liu, X., Shao, Y., Zhou, J., Qian, G., & Ma, Z. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.11.007 · Cited by 46
P4HB: A novel diagnostic and prognostic biomarker for bladder carcinoma
Wu, Y., Peng, Y., Guan, B., He, A., Yang, K., He, S., Gong, Y., Li, X., & Zhou, L. (2020) · Oncology Letters · doi:10.3892/ol.2020.12356 · Cited by 47
Podrimaj-Bytyqi, A., Borovečki, A., SELIMI, Q. I., Manxhuka-Kërliu, S., Gashi, G., & Elezaj, I. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-35903-5 · Cited by 46
Global Patterns and Trends in Pancreatic Cancer Incidence
Luo, G., Zhang, Y., Guo, P., Ji, H., Xiao, Y., & Li, K. (2019) · Pancreas · doi:10.1097/mpa.0000000000001230 · Cited by 46
Aly, A., Johnson, C. W., Yang, S., Botteman, M. F., Rao, S. A., & Hussain, A. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1591424 · Cited by 46
Metadata
- Authors
- Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F.
- Affiliations
- Centre international de recherche sur le cancer (FR)
- American Cancer Society (US)
- Corresponding author
- Bray, Freddie
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 71
- Issue
- 1
- Pages
- 96-108
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2473162054
- Cited by
- 2,514
- References
- 55
- Citations by year
- 2026: 79 · 2025: 165 · 2024: 248 · 2023: 244 · 2022: 314 · 2021: 414 · 2020: 400 · 2019: 306 · 2018: 225 · 2017: 102
- FWCI
- 21.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Urology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
- Keywords
- bladder cancer, cancer incidence, cancer mortality, incidence trends, sex differences, smoking, Schistosoma haematobium, etiology, global cancer statistics
- MeSH terms
- Urinary Bladder Neoplasms, Female, Humans, Male, Registries, Risk Factors, Smoking, Global Health, Incidence, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
